ImmunityBio (IBRX) Payables (2014 - 2026)

ImmunityBio (IBRX) has reported Payables for 13 consecutive years, with $500000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables rose 150.0% year-over-year to $500000.0; the TTM figure through Mar 2026 stood at $500000.0 (up 150.0% YoY), while the FY2025 annual figure was $7.0 million, up 3933.53% from the prior year.
• Payables fell to $500000.0 in Q1 2026 per IBRX's latest filing, from $7.0 million in the prior quarter.
• Across five years, Payables topped out at $481.9 million in Q2 2023 and bottomed at $112000.0 in Q2 2025.
• Historically, Payables has averaged $82.2 million across 5 years, with a median of $400000.0 in 2025.
• Annual changes were most pronounced in 2023 — Payables tumbled 99.97% — and 2025, when it surged 3933.53%.
• ImmunityBio's Payables stood at $432.9 million in 2022, then sank by 99.97% to $136000.0 in 2023, then rose by 27.21% to $173000.0 in 2024, then soared by 3933.53% to $7.0 million in 2025, then tumbled by 92.83% to $500000.0 in 2026.
• Business Quant data shows IBRX's Payables at $500000.0 in Q1 2026, $7.0 million in Q4 2025, and $300000.0 in Q3 2025.